Mankind Pharma Limited
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.
In our domestic pharmaceuticals business, our product portfolio comprises a road range of formulation across various acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti- diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory.
Brand
Mankind has 10 brand families, 19 brand families, and 36 brand families with Domestic Sales over ₹200 crores, ₹100 crores, and ₹50 crores, respectively. Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold.
Network
The company operates 25 manufacturing facilities across India, in Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh, Maharashtra, and Uttarakhand with a total installed capacity of 42.05 billion units per annum across a wide range of dosage forms.
Shareholding Pattern
- Public Group
- Promoter
Financial Summary
| Particulars | March 2023 | March 2022 | March 2021 |
| Sales | 8,127 | 7,486 | 5,523 |
| Sales Growth % | 8.56% | 35.54% | 15.20% |
| Operating Profit | 1,698 | 1,842 | 1,372 |
| OPM % | 21% | 25% | 25% |
| Profit after tax | 1,248 | 1,389 | 1,084 |
| YOY Growth | – | 7% | 7% |
| EPS in Rs | 31.16 | 34.68 | 27.07 |
Final Outlook
Mankind’s consumer healthcare business expanded 10% YoY due to higher rural penetration for its key brands, Manforce and Prega News, while its branded prescription business grew 18% YoY, primarily driven by core therapies of anti-infective, respiratory, and GI. Chronic therapy’s quarter-over-quarter contribution increased to 35% from 33% in FY22.
In comparison to its counterparts, humanity is less prevalent in Tier 1 and urban areas, contributing only 53% of revenue as opposed to 63% from IPM(Indian Pharma Market). Nevertheless, in FY23, It has good amount of profitable results for both Q1 & Q2. As, per the Q2 It’s Consolidated net profit is increased by 21 per cent to Rs 511 crore due to increase in its healthcare Business. Moreover, It has collaborated with Spicejet for advertistment purposes and in its future growth their plan is to Achieve 100% plastic neutral at their factories as per EPR Target Plan approved by CPCB by FY24 and will also be focusing on increasing number of facilities to 25.
Disclaimer: The information provided here is for general informational purposes only and should not be considered as professional financial, investment, or legal advice.The user assumes all risks associated with their use of the information.
Mankind-Pharma-ltd